Back to Search
Start Over
Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles.
- Source :
-
Biomaterials [Biomaterials] 2014 Jan; Vol. 35 (1), pp. 601-10. Date of Electronic Publication: 2013 Oct 16. - Publication Year :
- 2014
-
Abstract
- The hepatocyte growth factor receptor (HGFR, c-Met or Met) is a receptor tyrosine kinase that is involved in embryogenesis, tissue regeneration and wound healing. Abnormal activation of this proto-oncogene product is implicated in the development, progression and metastasis of many cancers. Current therapies directed against Met, such as ligand- or, dimerization-blocking antibodies or kinase inhibitors, reduce tumor growth but hardly eradicate the tumor. In order to improve anti-Met therapy, we have designed a drug delivery system consisting of crosslinked albumin nanoparticles decorated with newly selected anti-Met nanobodies (anti-Met-NANAPs). The anti-Met NANAPs bound specifically to and were specifically taken up by Met-expressing cells and transported to lysosomes for degradation. Treatment of tumor cells with anti-Met NANAPs also resulted in downregulation of the total Met protein. This study shows that anti-Met NANAPs offer a potential system for lysosomal delivery of drugs into Met-positive tumor cells.<br /> (Copyright © 2013 Elsevier Ltd. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1878-5905
- Volume :
- 35
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Biomaterials
- Publication Type :
- Academic Journal
- Accession number :
- 24139763
- Full Text :
- https://doi.org/10.1016/j.biomaterials.2013.10.001